Abstract
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Highlights
The retina is supplied with oxygen, nutrients, and waste exchanges by two distinct vascular beds: the retinal and choroidal capillary networks
To investigate whether ANG-2 is a suitable pharmacological target for human retinal vascular diseases, we measured the levels of ANG-1 and ANG-2 in the vitreous of patients newly diagnosed with wet age-related macular degeneration (AMD), diabetic retinopathy (DR), proliferative DR, or retinal vein occlusion (RVO) in comparison with macular hole as controls, as described in Koss et al (2011)
The efficacy of intravitreal ranibizumab has been demonstrated in patients with choroidal neovascularization (CNV) secondary to Wet age-related macular degeneration (wAMD) in the pivotal phase III studies MARINA and ANCHOR (Rosenfeld et al, 2006a,b; Chang et al, 2007; Brown et al, 2009)
Summary
The retina is supplied with oxygen, nutrients, and waste exchanges by two distinct vascular beds: the retinal and choroidal capillary networks. Abnormal leakage and/or neovascularization from retinal vessels are the hallmarks of diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) (Penn et al, 2008; Wang & Hartnett, 2016). Wet age-related macular degeneration (wAMD) develops when new vessels grow into the subretinal space from the underlying choroidal capillary network underneath the outer retina (Campochiaro, 2013). Anti-VEGF-A-based therapies are the standard of care for a variety of solid tumor indications and ocular neovascular diseases, such as wAMD, DME, and RVO. One way of enhancing the efficacy of anti-VEGF-A-based therapies is adding the inhibition of another soluble factor to the therapeutic reagent that is essential for angiogenesis (Jo et al, 2006)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
